Yakin Medic is described as a provider of active live stem cell therapies.
Malaysia-based Yakin Medic plans to raise RM100 million from an IPO on the Catalist board of the Singapore Exchange (SGX:S68
) , reports The Edge Malaysia, The Star, The Sun and various other Malaysian papers.
The IPO, targeted for 4Q this year or early 2026, is part of its broader growth bid.
